Corvus Pharmaceuticals reported positive Phase I data for soquelitinib, an oral ITK inhibitor, in moderate‑to‑severe atopic dermatitis cohorts, showing deepening responses at eight weeks and activity in patients previously treated with systemic agents. Early efficacy metrics—including high EASI response rates—drove a dramatic market reaction and accelerated plans for mid‑stage development. Company statements and follow‑on commentary emphasized soquelitinib’s potential to match or exceed injectable biologics in eczema and to expand into immune and oncology indications if tolerability holds in larger trials. Corvus said it will move the program into mid‑stage studies this quarter, with investors closely watching safety and longer‑term durability data.